Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Eur Urol Focus. 2018 Jul;4(4):509-511. doi: 10.1016/j.euf.2018.08.005. Epub 2018 Aug 23.
There are limited treatment options for patients with recurrent non-muscle-invasive bladder cancer. In this report, we will talk about the history of photodynamic therapy; although it showed encouraging therapeutic results, it was largely abandoned due to toxicity or bystander effects on normal cells. Monoclonal antibody-conjugates represent an emerging therapeutic approach for malignancies that improves upon tumor specificity. The use of a monoclonal antibody-photosensitizer conjugate is a more selective method of delivering light therapy and has been termed "photoimmunotherapy", which we will discuss in the last part of this report.
对于复发性非肌肉浸润性膀胱癌患者，治疗选择有限。在本报告中，我们将讨论光动力疗法的历史；尽管它显示出令人鼓舞的治疗效果，但由于毒性或对正常细胞的旁观者效应，它在很大程度上被放弃了。单克隆抗体偶联物代表了一种治疗恶性肿瘤的新兴治疗方法，可提高肿瘤特异性。使用单克隆抗体-光敏剂偶联物是一种更具选择性的递送电疗方法，被称为“光免疫疗法”，我们将在本报告的最后一部分讨论。
